THE Therapeutic Goods Administration has issued a safety advisory in relating to dolutegravir, after preliminary results from a new study suggested risk of birth defects in babies born to women being treated with the medicine.
Dolutegravir is used to treat HIV infection in adults and children over 12, and is marketed in Australia under the brand name Tivicay.
The compound is also one of three active ingredients in Triumeq.
Early results of the Tsepamo Study conducted in Botswana identified a potential risk of neural tube defects in babies born to women with exposure to dolutegravir-containing regimens at the time of conception.
While the issue is being investigated the TGA has advised dolutegravir should not be used in women seeking to become pregnant
The above article was sent to subscribers in Pharmacy Daily's issue from 01 Jun 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Jun 18
